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Efficacy of temazepam in frequent users: a series of N-of-1 trials. Family Practice 2005; 22:
152–159.
Background. Benzodiazepines are frequently prescribed for sleep disturbances. However,
benzodiazepines are associated with side effects, and may be ineffective when used for a
prolonged period of time.
Objectives. To investigate for individual patients whether placebo was as effective as
temazepam, or whether 10 mg was as effective as 20 mg temazepam, and whether these results
influenced their future temazepam use.
Methods. A series of randomized double-blind N-of-1 trials were conducted in general
practices in The Netherlands for patients who were using temazepam regularly. Each patient
received five pairs of treatments consisting of one week of temazepam (10 or 20 mg) and one
week of the control intervention (placebo or 10 mg temazepam). Per pair, the sequence of
treatments was randomized. Main outcome measures were: time to fall asleep, and the
individual main complaint.
Results. Twelve out of 15 patients completed their trial. In three patients there was no
difference, in five a large difference, and in four a small difference in favour of temazepam.
At follow-up, seven patients had stopped or reduced their temazepam use.
Conclusion. The results regarding the efficacy of temazepam varied across patients. N-of-1
trials seem to be valuable in patients who are motivated to stop or reduce their temazepam use.
They clearly demonstrate the efficacy of temazepam, and may give patients additional
confidence to discontinue regular hypnotic use. The value of N-of-1 trials for patients who are
less motivated is unclear, as the size of treatment effect does not seem to influence future
hypnotic use.
Keywords. Benzodiazepines, hypnotics and sedatives, placebos, randomized controlled trials,
temazepam.
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Introduction
Benzodiazepines are frequently prescribed for sleep
disturbances.1 In 1998, the annual prevalence of
benzodiazepine use was estimated at 12.2% in The
Netherlands. At least one third of all users were long-term
users.2 However, there is considerable doubt about
whether benzodiazepines are still effective when used for
a prolonged period of time.3–5 Additionally, use of
benzodiazepines is associated with adverse cognitive
effects and an increased risk of motor vehicle accidents,
falls and fractures, especially among the elderly.6–8
Furthermore, benzodiazepines may interact with other
medication, such as antidepressants and antiepileptic
drugs, resulting in an intensified hypnotic effect.9
Therefore, in practice guidelines for the management of
insomnia it is recommended to prevent or stop long-term
use of benzodiazepines.3,5
However, attempts made by GPs and their patients to
stop long-term use of benzodiazepines are often
unsuccessful. Success rates varying from 13% to 59%
have been reported.10–15 The success of such an attempt
may be influenced by multiple factors, such as psycho-
logical and social factors, dependence on the hypnotic,
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the coaching given by the GP, and variation in the
effectiveness of the hypnotic across individuals. But
probably the most important obstacle for successful
stopping is the awareness of the patient of the abstinence
of his or her daily dose of benzodiazepines. N-of-1 trials
may provide more insight into the question whether the
use of hypnotics can be successfully reduced in individual
patients without loss of quality and quantity of sleep.
Because in N-of-1 trials both the patient and the GP are
blinded for the sequence of treatments, the potential
influence of expectations with regard to the effectiveness
of the hypnotic is precluded.
N-of-1 trials are carried out with one patient. The
patient is his or her own control, and receives alternately
the intervention treatment and the control treatment.
The sequence of treatments is randomized.16 N-of-1 trials
may help a GP to decide on a treatment policy when
there is doubt regarding the effectiveness of medication
for an individual patient. N-of-1 trials are especially
useful in patients with chronic conditions, and for
interventions that have a rapid onset and stop acting soon
after discontinuation.16 Several N-of-1 trials have been
carried out and their feasibility in clinical practice seems
to be promising.17–19 Since the purpose of N-of-1 trials is
to evaluate the effects of treatments for each individual
patient (and not to estimate the average effect for a larger
population), the size of a series of N-of-1 trials is of minor
importance. Nevertheless, a series of N-of-1 trials will be
able to demonstrate the potential variation in outcome
across individuals.
The first objective of this study was to investigate for
individual patients in general practice whether placebo
was as effective as temazepam (10 or 20 mg), or, in some
patients, whether 10 mg temazepam was as effective as
20 mg temazepam. The second objective was to
investigate whether presenting the personal results of the
N-of-1 trial to each individual patient influenced their
future use of temazepam.
Methods
Patient selection
Nine GPs from six different towns in The Netherlands
participated in the study. Between April and November
2001, they were asked to select patients from their
medical records who met the following criteria: regular
use of 10 mg or 20 mg temazepam as a hypnotic for at
least 4 nights a week during the past 2 months; at least
18 years of age; and no contra-indications for
benzodiazepines. Additionally, the patients had to be
able to fill in a questionnaire in Dutch and they had to
be able to visit the practice.
Design
The selected patients received information about the
study, and written informed consent was obtained. The
study comprised of a series of N-of-1 trials with a
duration of ten weeks. Before the start of their trial,
patients were asked about their motivation to
participate. To standardize the knowledge on sleep
hygiene for all patients, written recommendations for
sleep hygiene3 were given to and discussed with the
patient by the GP before the patients received any trial
medication. During the study, each patient received five
pairs of treatments. Each pair consisted of a one-week
period of treatment A and a one-week period of treat-
ment B (Fig. 1). A patient taking 10 mg temazepam before
the start of the study received placebo (treatment A)
versus 10 mg temazepam (treatment B) during the
study; a patient taking 20 mg temazepam before the
start of the study received either placebo or 10 mg
temazepam (treatment A) versus 20 mg temazepam
(treatment B) during the study, depending on the
patient’s willingness to either reduce the dosage or to
stop completely. Per pair of treatments, the sequence of
the two treatments was randomized.
The random sequence was prepared in advance by the
hospital pharmacist for each patient separately. The
patient, the GP and the investigator were blinded for the
sequence of treatments. To ensure blinding, identical
tablets with regard to colour, smell and taste were used
as placebo. If 10 mg temazepam was compared to 20 mg
temazepam, additional placebo tablets were given in 
the 10 mg temazepam treatment periods, so that the
patient received 2 tablets each night in all treatment
periods. Patients were not instructed to take the
medication daily, but every night they decided for
themselves whether or not to take the tablets. The
patients received the tablets in special boxes, in which
each section was coded with a date and contained the
tablets for that date. The patients were instructed to
leave the tablets they did not take in the boxes. In
addition, the patients were asked to indicate each day in
a diary whether or not they had taken any hypnotics. 
The study was approved by the Ethics Review Board of
the VU University Medical Center.
Outcome assessment
Outcomes were assessed by means of daily diaries. The
primary outcome measures were:
(1) the individual main outcome for which the
patient could select among the following
outcomes: time to fall asleep (minutes); the
patient’s perception of the night’s sleep (total
sleep time sufficient or not); the total sleep time
(hours); the number of times awake during the
night; the duration of the longest period awake
during the night (minutes); and the number of
complaints in the daytime (selected from a set of
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Did the patient use a dosage of 10 mg or 20 mg temazepam before the start of the study?
10 mg temazepam
  Is the patient willing to
  receive placebo as
  control medication?






  completed trial n=7
20 mg temazepam
  Is the patient willing to
  receive placebo as
  control medication?
10 mg temazepam 
(treatment A) versus
20 mg temazepam
  (treatment B) 
  n=3




  (treatment B) 
  n=5
  completed trial n=3
  Is the patient willing to
  receive 10 mg  
  temazepam as control 
  medication?
Yes No No Yes
No Yes
FIGURE 1 Flow diagram to determine the trial medication per individual
(2) independent of the individual main outcome, the
time to fall asleep (minutes).
All other outcome measures mentioned above were
considered as secondary outcome measures for each
individual patient. Furthermore, information was
collected on co-medication, alcohol intake and
afternoon naps. After analysis, plots of their scores on
primary and secondary outcome measures were shown
to the patients and discussed with them. Three months
later the patients were contacted by telephone and
asked how many times, and in which dosage, they had
taken temazepam during the previous 2 weeks.
Analysis
Since N-of-1 trials were conducted, all outcome measures
were analysed for each patient separately. Because of
the non-normal distribution of the data, median scores
were calculated for all continuous outcomes for each
treatment period (Fig. 2). Furthermore, for each
treatment period percentages were calculated for the
number of nights with a sufficient total sleep time and
for the number of days with at least one complaint in the
daytime. So-called ‘bad’ nights were defined as nights in
which the time to fall asleep was 60 minutes, or in
which the total sleep time was 5 hours. The percentage
of ‘bad’ nights was calculated for each treatment period.
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Finally, differences in the scores between the compared
treatments were calculated (Fig. 2).
A priori, cut off points were defined for the primary
outcome measures. A median difference in the time to
fall asleep, the total sleep time, or the longest period
awake during the night, of at least 30 minutes in favour of
temazepam was considered to be a large effect; 5 to 30
minutes a small effect; and 5 minutes no effect of
temazepam. For differences in the number of times
awake during the night and the number of complaints in
the daytime the cut off points for large, small and no
effect of temazepam were 1, between 0 and 1, and 0,
respectively. Finally, the cut off points for the number of
nights with sufficient sleep were a difference of 29% 
(2 nights in a week), between 0% and 29%, and 0%,
respectively for large, small, and no effect of temazepam.
All analyses were carried out according to the
intention-to-treat principle. For patients who took less
than 75% of the trial medication, an alternative analysis
was carried out, including only those days on which the
trial medication or additional benzodiazepines had been
taken (on-treatment analysis).
Assessment of the plots of the primary and secondary
outcome measures showed that there were no carry-over
effects, i.e. there were no consistently better results in the
first nights (compared to the latter nights) of a control
intervention period following a period of (highest dose of)
temazepam use or vice versa. Therefore, the results of all 7
days of each treatment period were entered in the analysis.
Results
Subjects
Fifteen patients were selected for participation: ten
women and five men (Table 1). Their age ranged between
45 and 78 years (median 62 years). Before the start of the
study, seven patients were taking 10 mg temazepam and
eight were taking 20 mg temazepam. Of the eight patients
who were taking 20 mg temazepam, five received placebo
versus 20 mg temazepam, and three received 10 mg
temazepam versus 20 mg temazepam during the study.
Three patients (numbers 13, 14 and 15) did not
complete the study: one because of nausea after a period
of 20 mg temazepam (patient no. 14 after a few days), and
two because of insomnia (no. 13 after a few days, after a
period of the lowest dose of temazepam; no. 15 after
5 weeks, after a period of 20 mg temazepam). Patient no.
15 took additional benzodiazepines during the last 12
days before she stopped the trial. All three patients took
20 mg temazepam before the start of the study.
Efficacy of temazepam
Twelve patients completed their 10-week trial period.
Before the patients were informed about the results of
their N-of-1 trial, they were asked whether they had any
idea when they had received the (highest dose of)
temazepam. Blinding turned out to be successful: none
of the twelve patients had noticed that they had taken
temazepam as well as the control treatment for periods
of one week.
For all patients, there were no or minor differences for
co-medication, alcohol intake and the number of
afternoon naps between temazepam and the control
intervention. The results of the N-of-1 trials regarding the
efficacy of temazepam varied across the patients
(Table 2). For three patients (nos 1, 2 and 3), the primary
outcomes (minutes to fall asleep and the individual main
outcome) showed no difference between the two
treatments compared. For three other patients (nos 10, 11
and 12), the time to fall asleep was at least 30 minutes in
favour of (the highest dose of) temazepam, and the
individual main outcome favoured (the highest dose of)
temazepam. For five other patients (nos 4, 5, 6, 7 and 8),
the primary outcomes favoured temazepam to a lesser
extent. Finally, in one patient (patient no. 9), the time to
median
placebo (treatment A)
t = 0             1            2             3            4            5            6            7            8            9           10 weeks































FIGURE 2 Example of randomization sequence for one patient comparing placebo (treatment A) and 10 mg temazepam
(treatment B), and analysis schedule
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fall asleep was only 5 minutes in favour of temazepam,
whereas the duration of the longest period awake during
the night (the individual main outcome for this patient)
was 40 minutes in favour of temazepam. For all patients,
there were no or only small differences for the number of
complaints in the daytime between temazepam and the
control intervention, which indicates no differences with
regard to possible withdrawal symptoms or side effects.
For five patients (nos 5, 6, 7, 10 and 12) the percentage of
‘bad’ nights was at least 29% (2 nights/week) in favour of
temazepam for one or both outcomes. For all other patients
the percentage of ‘bad’ nights showed no or only minor
differences between the two treatments (2 night/week).
On-treatment analysis
Ten of the twelve patients who completed the study took
at least 94% of the trial medication. The other two patients
took less than 75% of the medication (patient no. 2, 60%;
patient no. 7, 43%), so on-treatment analysis was carried
out. For patient no. 2 the on-treatment analysis showed
similar results as the intention-to-treat analysis for the
individual main outcome, but the time to fall asleep was
15 minutes in favour of placebo according to the on-
treatment analysis. For patient no. 7 the results of both
primary outcomes were more strongly in favour of
temazepam according to the on-treatment analysis. The
time to fall asleep was 49 minutes shorter during
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TABLE 1 Patient characteristics of 15 participants in N-of-1 trials on the efficacy of temazepam
Patient no. Gender Age Use of temazepam before start of trial Total duration of hypnotic use Trial medication 
(F = female, (any type or dose) (mg temazepam)
M = male)
1 M 47 7 nights/week 20 mg for 5 months 5 months 10 versus 20
2 F 78 7 nights/week 10 mg for 8.5 years 8.5 years 0 versus 10
3 F 48 7 nights/week 20 mg for 11 years 11 years 0 versus 20
4 M 62 6 to 7 nights/week 20 mg for 2 years 6.5 years 0 versus 20
5 M 74 4 to 5 nights/week 10 mg for 8 years 12 years 0 versus 10
6 F 56 7 nights/week 20 mg for 6 years 7 years 0 versus 20
7 F 57 5 nights/week 10 mg for 15 years 15 years 0 versus 10
8 F 45 7 nights/week 10 mg for 8 years 8 years 0 versus 10
9 F 72 7 nights/week 10 mg for 9 years 30 years with intervals 0 versus 10
10 F 73 7 nights/week 20 mg for years For years 10 versus 20
11 M 70 7 nights/week 10 mg for 6 months 6 months 0 versus 10
12 F 71 4 nights/week 10 mg for 8 years 12 years 0 versus 10
13 F 56 7 nights/week 20 mg for 3 years 3.5 years 10 versus 20
14 M 76 6 nights/week 20 mg for 4 months 4 months 0 versus 20
15 F 53 7 nights/week 20 mg for 2 years 2 years 0 versus 20
TABLE 2 Results for the 12 patients who completed their N-of-1 trial (negative scores favour (highest dose of) temazepam)
Patient no. Trial medication Median difference between treatments (range)
(mg temazepam)
Minutes to fall % nights with Minutes slept No. of times Time awake during
asleep sufficient sleep awake during the the night (minutes)
night
1 10 versus 20 0 (17.5; 35) 0 (29; 29) 0 (30; 60) 0 (1; 1) 0.25 (12.5; 7.5)
2 0 versus 10 0 (0; 0) 0 (14; 0) 15 (30; 30) 0 (0; 0) 0 (5; 0)
3 0 versus 20 0 (20; 0) 0 (40; 17) 30 (90; 60) 0 (0; 0) 0 (0; 0)
4 0 versus 20 15 (15; 15) 2 (14; 29) 0 (0; 60) 0 (1; 0) 7.5 (15; 0)
5 0 versus 10 12.5 (125; 0) 36 (43; 16) 45 (90; 30) 0.5 (1; 1) 2.5 (32.5; 0)
6 0 versus 20 5 (45; 10) 21 (57; 7) 75 (120; 30) __a 15 (30; 5)
7 0 versus 10 15 (30; 30) 14 (29; 36) 60 (60; 15) 0.25 (1; 0) 5 (45; 5)
8 0 versus 10 5 (30; 0) 26 (43; 14) 30 (60; 45) 0 (1; 0.5) 5 (7.5; 7.5)
9 0 versus 10 5 (12.5; 5) 43 (43; 12) 60 (180; 0) 1 (1.5; 0) 40 (205; 20)
10 10 versus 20 30 (45; 10) 9.6 (14; 29) 0 (45; 60) 0 (0.5; 1) 2.5 (20; 80)
11 0 versus 10 30 (60; 0) 43 (46; 12) 45 (90; 15) 1 (1; 0.5) 0 (17.5; 15)
12 0 versus 10 45 (90; 10) 43 (55; 19) 90 (120; 30) 0.5 (1; 1) 5 (10; 2.5)
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temazepam use and the percentage of nights with
sufficient total sleep time was 30% in favour of
temazepam, according to the on-treatment analysis.
Efficacy of temazepam and follow-up
After presenting the results of the primary and
secondary outcome measures to the patients, they were
asked about their intentions with regard to future
temazepam use (Table 3). All three patients for whom
the primary outcomes showed no difference between
the treatments (nos 1, 2 and 3) intended to stop or
reduce the use of temazepam. At three months follow-
up one patient (no. 1) again used temazepam as before
the study. Three of the four patients who showed a small
benefit of temazepam (nos 4, 6 and 8) intended to stop
or reduce the use of temazepam, but only two persisted
in this intent at three months follow-up. Finally, three of
the five patients with large effects of temazepam (nos 9, 10,
and 11) had stopped or reduced the use of temazepam at
three months follow-up as intended shortly after the
trial. In sum, seven of the 12 patients had stopped
(3 patients) or reduced (4 patients) temazepam use at
follow-up. There seemed to be only a weak association
between the efficacy of temazepam and the intentions
regarding future temazepam use, and no association
between the efficacy of temazepam and the actual
hypnotic use at follow-up.
Motivation to participate
Nine of all 15 patients indicated at baseline participated
in the study because they wanted to stop or reduce their
use of temazepam. Five patients participated for the
benefit of science and one because “he was asked to
participate by the GP’s assistant” (Table 3). This last patient
(no. 14) did not complete his trial. Of the nine patients
who were motivated to reduce their temazepam use, two
did not complete their trial (nos 13 and 15), six stopped
or reduced the use of temazepam at three months
follow-up (nos 2, 3, 6, 8, 9, and 11), and only one used
temazepam as before the study (no. 7). Among the five
patients who participated to benefit science, one patient
had reduced the use of temazepam (no. 10) and four
used temazepam as before the study (nos 1, 4, 5, and 12)
at the three months follow-up.
Discussion
In a series of randomized, blinded N-of-1 trials we
investigated the efficacy of temazepam in frequent users
of hypnotics. Twelve of the fifteen patients (80%)
completed the 10-week trial period. The results among
the 12 completers varied from no difference to large
differences in favour of (the highest dose of) temazepam.
The results did not seem to be associated with the dosage
of temazepam used during the trial. For example, among
the three patients who experienced no effect of
temazepam, one patient received placebo versus 10 mg
temazepam, another 10 mg versus 20 mg temazepam,
and the third placebo versus 20 mg temazepam.
Large-scale trials have shown that attempts to stop
temazepam use are only successful in 13 to 59% of
patients.10–15 There is little evidence regarding the factors
that may predict which patients can or cannot
successfully reduce the use of temazepam. Age under
6510 has been reported to be associated with a successful
attempt, but this evidence is not consistent across studies.
In our series age did not seem to influence outcomes.
TABLE 3 Results for the 15 participants in N-of-1 trials: motivation to participate, efficacy of temazepam, intended future use of hypnotics, and
hypnotic use three months after presenting the outcomes
Patient no. Motivation to participate in Efficacy of temazepam Intended medication Medication after 3 months
N-of-1 trial use after trial
1 S No effect Reduce dose and freq As before study
2 P No effect Reduce freq Reduced freq
3 P No effect Stop Stopped
4 S Small effect Reduce freq As before study
5 S Small effect As before study As before study
6 P Small effect Reduce freq Reduced freq
7 P Large effect (on-treatment As before study As before study
analysis)
8 P Small effect Reduce freq or stop Reduced freq
9 P Large effect Stop Stopped
10 S Large effect Reduce dose and freq Reduced dose and freq
11 P Large effect Stop Stopped
12 S Large effect As before study As before study
13a P – – –
14a O – – –
15a P – – –
P = Patient motivated to stop or reduce temazepam use; S = for the benefit of science; O = other (asked by the GP’s assistant); freq = frequency.
a Patient numbers 13, 14 and 15 did not complete their trial.
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Cormack et al. demonstrated that a relatively low
consumption of benzodiazepines11 was associated with a
successful attempt. However, in our series, none of the
three patients taking temazepam five or less times a week
at baseline, intended to stop or reduce temazepam use
after the trial. Due to the less frequent use of temazepam
compared to the other patients in the study, it may be
harder to achieve a reduction in the frequency of
temazepam intake.
N-of-1 trials demonstrate the efficacy of temazepam in
each individual patient, and may thereby provide a good
indication of the possibility to reduce hypnotic use.
However, in our series, the actual results of the trials did
not seem to be a strong predictor of future use of
temazepam. Patients decided either to stop, reduce, or
continue the use of hypnotics regardless of the effect
of temazepam shown by their trial. While the influence of
treatment effect appeared to be limited, the motivation
of the patients to participate in the study seemed to be of
greater importance. Six of the seven patients who
completed their trial and had indicated that they
participated in the study because they wanted to reduce
temazepam intake, successfully reduced temazepam use
during follow-up. In contrast, out of the five completers
who participated for the benefit of science only one
reduced the intake of hypnotics.
The potential influence of motivation to change
behaviour has been demonstrated in other research. In
an intervention study among 72 long-term benzodia-
zepine users Morrison12 found that it was significantly
more likely that the patient would stop taking the drug if
they originally wished to do so.
The question arises whether the patients with a
(strong) internal motivation needed the N-of-1 trial to
change hypnotic intake. In our opinion, the participation
in an N-of-1 trial may strengthen the intent to change
hypnotic use. Eight of the nine patients who intended to
reduce temazepam intake stated that the N-of-1 trial had
contributed to this decision. By participating in a trial the
patients are given more attention to their use of
temazepam and become more aware of their frequent
hypnotic use. This attention itself may be of more
importance than the results of the individual trials to
stimulate the patients to stop or reduce the temazepam
intake. In addition, for patients who are willing to reduce
temazepam intake, but are somewhat afraid to do so, an
N-of-1 trial may be more effective than an unblinded
attempt to reduce intake. The awareness of abstinence of
temazepam may cause insomnia, which may negatively
influence the success of the attempt. The fact that the
blinded design of an N-of-1 trial may facilitate the
attempt to reduce drug use is illustrated by a statement
made by patient no. 3:
“For a long period of time [before the study],
I wanted to stop, but I was uncertain whether I
could hang on. Because of the project I had to
persist. All the time during the trial, I slept
reasonably well, and it made no difference what I
took [temazepam or placebo]. Therefore I stopped
[taking sleep medication].”
At follow-up, seven of the 12 patients who completed
the trial, had stopped or reduced their temazepam
intake. Therefore, double-blinded N-of-1 trials may be
viewed as an instrument for GPs to reduce the
unnecessary temazepam use of their patients, especially
for those who are willing but somewhat afraid to do so.
Blinding of patients was successful, unexpectedly even
for patients in whom temazepam favoured placebo (or
lower dosage of temazepam) to a larger extent. This may
be explained by the fact that quality and quantity of sleep
varied across nights regardless of the type of treatment,
meaning that patients were not always sleeping well when
taking temazepam, and not always sleeping badly when
taking the control intervention. The latter can also be
concluded from the range in outcomes within the patients
presented in Table 2. Furthermore, for all patients, there
were no or only small differences for the number of
complaints in the daytime (possible withdrawal symptoms
or side effects) between temazepam and the control
intervention, which helped to ensure blinding.
The drop-out rate in our study was relatively low (3 of
the 15 patients). To prevent drop-out due to the length of
the trial period, we wanted to keep the trial period as short
as possible. However, this also implies that the power,
which depends on the number of treatment pairs, is
limited. These aspects should be weighed against each
other when designing an N-of-1 trial.20 The power of a
study is also related to the type of significance testing.
Although significance testing may be possible in N-of-1
trials, our data were not suitable for quantitative analysis,
partly due to the non-normal distribution of the data.
More importantly, we did not investigate whether one
treatment was better than the other, but whether one
treatment was equally effective as the other. In other
words, the N-of-1 trials were equivalence trials, rather than
superiority trials. This implies that conventional
significance testing could not be used for analysis.21 This
topic was also addressed in a reaction to a series of N-of-1
trials by March et al., in which it was pointed out that
failure to find a significant difference in favour of a
treatment may not be regarded as proof of equivalence.22,23
As a consequence, we decided to formulate a priori cut off
points, which were very helpful to determine the
magnitude of treatment effect, and to identify the variation
in efficacy of temazepam across patients.
In conclusion, N-of-1 trials provide clear evidence about
the impact of temazepam on the quality and quantity of
sleep in individual frequent users of hypnotics. In patients
who are motivated to stop or reduce their temazepam
intake, participation in the trial may give additional
confidence to successfully reduce temazepam use. The
value of N-of-1 trials for patients who are less motivated is
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unclear, as the size of treatment effect does not seem to
influence future use of hypnotics. For less motivated
patients experiencing small or no effect of temazepam,
additional coaching by the GP, and education about the
potential risks and disadvantages of long-term or frequent
use of hypnotics may offer possibilities to reduce their
unnecessary temazepam use. For patients experiencing
large benefits and no potential disadvantages of
temazepam, continued use of temazepam could be
justified. Our study demonstrated that there is a realistic
potential that N-of-1 trials are helpful in reducing
benzodiazepine use in primary care. The next step could be
to study, in a randomized clinical trial, whether N-of-1 trials
are more successful than other interventions in primary
care to reduce unnecessary temazepam use.24 Finally, the
design and execution of N-of-1 trials is time-consuming.
Therefore, also the applicability of N-of-1 trials in general
practice needs further study, in order to assess the
possibilities of implementing these trials in daily practice.
Acknowledgement
We wish to thank all the GPs and their patients who
participated in the study.
Declaration
Funding: this study was supported unconditionally by
Leo Pharma, The Netherlands.
Ethical approval: the study was approved by the Ethics
Review Board of the VU University Medical Center.
Conflicts of interest: none.
References
1 Kruse WH. Problems and pitfalls in the use of benzodiazepines in
the elderly. Drug Saf 1990; 5: 328–344.
2 Gorgels WJMJ, Oude Voshaar RC, Mol AJJ, Breteler MHM,
Lisdonk EH van de, Zitman FG. Long-term use of
benzodiazepines. [In Dutch: Het langdurig gebruik van
benzodiazepinen.]. Ned Tijdschr Geneeskd 2001; 145:
1342–1346.
3 Knuistingh Neven A, Graaff WJ de, Lucassen PLBJ et al. National
practice guideline for insomnia and hypnotics (Dutch College
of General Practitioners). [In Dutch: NHG-Standaard
Slapeloosheid en slaapmiddelen.]. In Rutten GEHM, Thomas S
(eds). NHG-Standaarden voor de huisarts. Utrecht: Bunge;
1993, 264–277.
4 Lader MH. Limitations on the use of benzodiazepines in anxiety
and insomnia: are they justified? European
Neuropsychopharmacology 1999; 9(Suppl 6): S399–S405.
5 Blow FC (consensus panel chair). Substance Abuse Among Older
Adults. Treatment Improvement Protocol (TIP) Series 26.
Rockville: US Department of Health and Human Services
(DHHS), 1998.
6 Thomas RE. Benzodiazepine use and motor vehicle accidents.
Systematic review of reported association. Can Fam Physician
1998; 44: 799–808.
7 Ray WA, Fought RL, Decker MD. Psychoactive Drugs and the
Risk of Injurious Motor Vehicle Crashes in Elderly Drivers.
Am J Epidemiol 1992; 136: 873–883.
8 Herings RM, Stricker BH, de Boer A, Bakker A, Stuurmans F.
Benzodiazepine and the risk of falling leading to femur
fractures. Dosage more important than elimination half-life.
Arch Intern Med 1995; 155: 1801–1807.
9 Van Loenen AC. Central nervous system (mental disorders). [In
Dutch: centrale zenuwstelsel (psychische aandoeningen)] In
van Loenen AC (ed.) Farmacotherapeutisch Kompas 2002.
Amstelveen: College voor zorgverzekeringen (CVZ); 2001,
53–135.
10 Holden JD, Hughes IM, Tree A. Benzodiazepine prescribing and
withdrawal for 3234 patients in 15 general practices. Fam Pract
1994; 11: 358–362.
11 Cormack MA, Owens RG, Dewey ME. The effect of minimal
interventions by general practitioners on long-term
benzodiazepine use. J R Coll Gen Pract 1989; 39: 408–411.
12 Morrison JM. Audit and follow-up of chronic benzodiazepine
tranquillizer use in general practice. Fam Pract 1990; 7:
253–257.
13 Morrice A, Iliffe S. Advising patients on their benzodiazepine use.
Br J Gen Pract 1990; 40: 83.
14 Cormack MA, Sweeney KG, Hughes-Jones H, Foot GA. Evaluation
of an easy, cost-effective strategy for cutting benzodiazepine use
in general practice. Br J Gen Pract 1994; 44: 5–8.
15 Hopkins DR, Sethi KBS, Mucklow JC. Benzodiazepine withdrawal
in general practice. J R Coll Gen Pract 1982; 32: 758–762.
16 Guyatt G, Sackett D, Adachi J et al. A clinician’s guide for
conducting randomized trials in individual patients. Can Med
Assoc J 1988; 139: 497–503.
17 Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD,
Newhouse MT. The n-of-1 randomized controlled trial: clinical
usefulness, our three-year experience. Ann Intern Med 1990;
112: 293–299.
18 Larson EB, Ellsworth AJ, Oas J. Randomized clinical trials in single
patients during a 2-year period. J Am Med Assoc 1993; 270:
2708–2712.
19 Patel A, Jeaschke R, Guyatt GH, Keller JL, Newhouse MT. Clinical
usefulness of n-of-1 randomized controlled trials in patients
with nonreversible chronic airflow limitation. Am Rev Respir
Dis 1991; 144: 962–964.
20 Campbell MJ. Commentary: statistical aspects. Br Med J 2004; 328:
506.
21 Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equiva-
lence: the importance of rigorous methods. Br Med J 1996; 313:
36–39.
22 March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P. N of 1
trials comparing a non- steroidal anti-inflammatory drug with
paracetamol in osteoarthritis. Br Med J 1994; 309: 1041–1045;
discussion 1045–1046.
23 Senn S, Bakshi R, Ezzet N. Caution in interpretation needed.
[letter] Br Med J 1995; 310: 667.
24 Mahon J, Laupacis A, Donner A, Wood T. Randomised study of n




niversiteit - Library on M
arch 15, 2011
fam
pra.oxfordjournals.org
D
ow
nloaded from
 
